Lenz & Staehelin advised Asceneuron in its Series C financing.Asceneuron SA, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a root cause…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
